Mary Steinbach, DNP, APRN, discusses emerging ASH 2025 data from the phase 2 iMMagine-1 registrational study (Abstract 256) showing that the BCMA CAR-T therapy anitocabtagene autoleucel demonstrated very high response rates and a favorable safety profile, including minimal neurotoxicity, even in heavily pretreated patients with relapsed/refractory multiple myeloma. She emphasizes that these findings support a shift toward using CAR-T earlier in treatment, with important implications for clinical workflows, earlier referrals, and long-term patient management by advanced practitioners.
In this video, Mary Steinbach, DNP, APRN, reviews ASH 2025 data from the phase III MajesTEC-3 trial (Abstract LBA-6), showing that the bispecific antibody teclistamab plus daratumumab significantly improves progression-free survival and depth of response compared with standard regimens in relapsed/refractory multiple myeloma. This is important for advanced practitioners because the findings supporting use of BCMA bispecific therapy as a potential second-line standard come with important implications for treatment sequencing, side effect management, and outpatient care workflows.
In this video, Mary Steinbach, DNP, APRN, highlights elranatamab as a highly effective and reliable BCMA bispecific, with ASH 2025 data confirming both strong real-world performance and future potential in combination and earlier-line settings. Optimal outcomes depend on well-designed care systems—particularly around step-up dosing, cytopenia and infection management, and outpatient workflows—positioning advanced practice providers as central to maximizing patient benefit.
